Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adebrelimab + bevacizumab
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Adebrelimab + bevacizumab is a combination therapy consisting of two distinct drugs. Adebrelimab is an anti-PD-L1 monoclonal antibody that works by blocking the interaction between PD-L1 and its receptor, enhancing T-cell immune responses against cancer cells. Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that inhibits vascular endothelial growth factor (VEGF), preventing its binding to VEGFR-1 and VEGFR-2 receptors. This inhibits angiogenesis (new blood vessel formation), cell proliferation, and tumor growth. The combination is being investigated for various cancer types, particularly in refractory settings where standard treatments have failed.
- Brand names
- AiruikaAvastin
- Other names
- adbelimumab + bevacizumabSHR-1316 + bevacizumab
02
Targets
VEGFA (Vascular endothelial growth factor A)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on adebrelimab + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adebrelimab + bevacizumab.